Facts of Ocrevus (ocrelizumab)
OCREVUSTM (ocrelizumab) injection, for intravenous use
Initial U.S. Approval: 2017
Injection: 300 mg/10 mL (30 mg/mL) in a single-dose vial.
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Ocrevus (ocrelizumab) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Ocrevus (ocrelizumab) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What Ocrevus is?
OCREVUS is a prescription medicine used to treat:
- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Primary progressive MS, in adults.
What ocrelizumab is?
Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds